Press release
Metastatic Renal Cell Carcinoma Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight
Metastatic Renal Cell Carcinoma Clinical Trials
The Metastatic Renal Cell Carcinoma market is rapidly evolving with cutting-edge research and breakthrough therapies driven by leading companies like AstraZeneca, Genentech, Sumitomo Dainippon Pharma, and Allogene Therapeutics. These innovators are revolutionizing treatment approaches and shaping the future of Metastatic Renal Cell Carcinoma care, offering new hope for patients worldwide.
For emerging Metastatic Renal Cell Carcinoma drugs, the Metastatic Renal Cell Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report
• DelveInsight's Metastatic Renal Cell Carcinoma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline drugs for Metastatic Renal Cell Carcinoma treatment.
• The leading Metastatic Renal Cell Carcinoma companies include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd., Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., and others are evaluating their lead assets to improve the Metastatic Renal Cell Carcinoma treatment landscape.
• Key Metastatic Renal Cell Carcinoma pipeline therapies in various stages of development include Atezolizumab, Olaparib, TP-1454, and others.
• In March 2025, Oncorena announced that the FDA has approved its IND application for the Phase I/II Oncorella-1 study (NCT05287945, ONC001-CL-001), which will evaluate the safety, tolerability, and anti-tumor efficacy of orellanine in patients with metastatic clear-cell or papillary renal cell carcinoma.
• In February 2025, Telix Pharmaceuticals announced the FDA accepted the Biologics License Application for TLX250-CDx, a novel imaging agent for kidney cancer, granting it Priority Review. This brings Telix closer to potentially launching the first imaging agent to diagnose clear cell renal cell carcinoma accurately.
Request a sample and discover the recent breakthroughs happening in the Metastatic Renal Cell Carcinoma pipeline landscape @ https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Metastatic Renal Cell Carcinoma Overview
Renal cell carcinoma (RCC) is the most prevalent form of kidney cancer in adults, accounting for approximately 85% of kidney-originating tumors. The disease often remains undetected for much of its progression, with only 10% of patients exhibiting the classic triad of flank pain, hematuria, and a palpable flank mass.
Metastatic spread occurs in around 33% of RCC cases, posing significant challenges in clinical management due to the limited effectiveness of available treatments. RCC commonly metastasizes to the lungs, liver, bones, brain, and adrenal glands, though it has been reported to spread to nearly any part of the body. The metastatic process frequently involves multiple organ systems and may be present at diagnosis or emerge at some point after nephrectomy. Between 20% and 50% of patients eventually develop metastatic disease following nephrectomy, with a shorter interval between surgery and metastasis linked to a poorer prognosis.
The outlook for metastatic RCC remains poor, with a median survival of only 6 to 12 months and a 2-year survival rate of 10% to 20%.
Find out more about Metastatic Renal Cell Carcinoma medication @ https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Metastatic Renal Cell Carcinoma Treatment Analysis: Drug Profile
Olaparib: AstraZeneca
Olaparib is a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, specifically PARP1 and PARP2. As part of a novel class of anti-cancer therapies, PARP inhibitors exploit defects in DNA repair mechanisms in cancer cells with BRCA mutations, ultimately inducing cell death. Olaparib is approved for the treatment of various BRCA-associated cancers, including ovarian, breast, pancreatic, and prostate cancer. Initially approved by the FDA and EU in December 2014, the drug is currently undergoing Phase II clinical trials for the treatment of metastatic renal cell carcinoma.
Atezolizumab: Genentech
Atezolizumab is a humanized IgG antibody that targets PD-L1, blocking its interaction with PD-1 and B7-1. By preventing PD-L1 from binding to PD-1, it enhances anti-tumor immune responses without triggering antibody-dependent cellular cytotoxicity. This therapy is specifically indicated for patients whose tumors express PD-L1, those ineligible for platinum-based chemotherapy, or those whose tumors do not respond to platinum-based treatment. Atezolizumab received FDA approval on October 18, 2016, and is currently in Phase III clinical trials for the treatment of metastatic renal cell carcinoma.
Key Metastatic Renal Cell Carcinoma Therapies and Companies
• Olaparib: AstraZeneca
• TP-1454: Sumitomo Dainippon Pharma
• Atezolizumab: Genentech
Learn more about the novel and emerging Metastatic Renal Cell Carcinoma pipeline therapies @ https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Metastatic Renal Cell Carcinoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Scope of the Metastatic Renal Cell Carcinoma Pipeline Report
• Coverage: Global
• Key Metastatic Renal Cell Carcinoma Companies: AstraZeneca (LSE: AZN), Genentech (a member of the Roche Group, SIX: ROG), Sumitomo Dainippon Pharma (TSE: 4506), Allogene Therapeutics (NASDAQ: ALLO), Nektar Therapeutics (NASDAQ: NKTR), Eli Lilly and Company (NYSE: LLY), Xynomic Pharmaceuticals (formerly NASDAQ: XYN, now private), AnewPharma (private), HUTCHMED (NASDAQ: HCM; HKEX: 13), MedImmune (subsidiary of AstraZeneca, not publicly traded), Incyte Corporation (NASDAQ: INCY), NiKang Therapeutics (private), OncoC4, Inc. (private), Nanobiotix (NASDAQ: NBTX; Euronext: NANO), Aravive (NASDAQ: ARAV - now delisted due to bankruptcy), Mirati Therapeutics Inc. (NASDAQ: MRTX - acquired by BMS), BeiGene (NASDAQ: BGNE; HKEX: 6160; SSE: 688235), Shanghai PerHum Therapeutics Co., Ltd. (private), Akeso Biopharma (HKEX: 9926), Novartis Pharmaceuticals (SWX: NOVN), Vaccibody (now Nykode Therapeutics, Euronext Growth Oslo: NYKD), SillaJen, Inc. (KOSDAQ: 215600), Chongqing Precision Biotech Co., Ltd. (private), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI - now defunct), SOTIO Biotech AG (private, part of PPF Group), Pfizer (NYSE: PFE), Peloton Therapeutics, Inc. (acquired by Merck, formerly private), and NeoTX Therapeutics Ltd (private).
• Key Metastatic Renal Cell Carcinoma Pipeline Therapies: Atezolizumab, Olaparib, TP-1454, and others.
Dive deep into rich insights for drugs used for Metastatic Renal Cell Carcinoma treatment; visit @ https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Introduction
2. Executive Summary
3. Metastatic Renal Cell Carcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Metastatic Renal Cell Carcinoma Pipeline Therapeutics
6. Metastatic Renal Cell Carcinoma Pipeline: Late-Stage Products (Phase III)
7. Metastatic Renal Cell Carcinoma Pipeline: Late-Stage Products (Phase III)
8. Metastatic Renal Cell Carcinoma Pipeline: Mid-Stage Products (Phase II)
9. Metastatic Renal Cell Carcinoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Renal Cell Carcinoma Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight here
News-ID: 3959229 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
